Bioxytran, Inc. (BIXT)

OTCMKTS · Delayed Price · Currency is USD
0.0440
0.00 (0.00%)
At close: Mar 6, 2026
-43.59%
Market Cap 4.98M
Revenue (ttm) n/a
Net Income (ttm) -2.35M
Shares Out 113.18M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 151,325
Average Volume 221,512
Open 0.0449
Previous Close 0.0440
Day's Range 0.0409 - 0.0450
52-Week Range 0.0342 - 0.2283
Beta 2.33
RSI 42.85
Earnings Date Mar 27, 2026

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol BIXT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.